Cancer Vaccine

Also found in: Wikipedia.
A vaccine that either prevents infections with cancer-causing viruses—e.g., HPV—treats existing cancer or prevents the development of cancer in certain high risk individuals. The first effective cancer vaccine is that for preventing cervical cancer. Dendreon Corp’s Provenge, a vaccine for advanced prostate cancer, was approved by the FDA in 2010 and adds about 4 months of life to the average person’s lifespan, at an estimated cost of $100,000. Other CV candidates include peptides, proteins, whole cancer cells, dendritic cells, gangliosides, heat-shock proteins, viral and bacterial vectors, and oligonucleotides
References in periodicals archive ?
Clinical study of the personalized cancer vaccine is anticipated to begin in 2017.
Moderna will also utilize the upfront payment to fund a portion of the build-out of a GMP manufacturing facility in suburban Boston for the purpose of personalized cancer vaccine manufacturing.
UKPRwire, Tue May 06 2014] The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
The cancer vaccine market comprises of the prophylactic and the therapeutic sectors, and while there are interesting developments expected in both, it is the latter that offers the most inspiring innovations.
The first-ever therapeutic cancer vaccine was approved for the treatment of prostate cancer in April.
To test the hypothesis, Repasky and her colleagues John Subject and Sherry Evans, also of Roswell Park, administer a cancer vaccine to mice with a form of breast cancer.
AustCancer sees its leading edge anti-idiotypic cancer vaccine Pentrys as an obvious candidate for evaluation with the Galenica adjuvants.
Scientists have yet to create a so-called cancer vaccine that reliably primes the immune system to recognize malignant cells and target them for destruction.
Onyvax-P is a therapeutic prostate cancer vaccine designed to elicit a powerful and specific immune response against prostate cancer cells without the severe side effects often associated with conventional cancer therapies.
His group plans to directly compare the kidney cancer vaccine, which had a similar immune-response rate, with the current treatment standard of chemotherapy and immune-stimulating chemicals such as interferon.

Full browser ?